Pranetra Lifesciences LLP
YOUR VISION OUR SOLUTION
Expertise in developing raw materials, intermediates, fine chemicals and technologies, crystallization, polymorph and particle size distribution (PSD).
Situated in Manesar, Gurgaon and having a state-of-the-art facility over 7000 sq ft area, Pranetra is home to a team of dedicated chemists who are at the forefront of inventing innovative products and services.
| CAS No | Structure | IUPAC Name | Application |
|---|---|---|---|
| 24190-77-0 |
|
Methyl-4-acetamido-5-chloro-2-hydroxybenzoate | Prucalopride Succinate |
| 4093-28-1 |
|
4-Acetylamino-2-hydroxy-benzoic acid methyl ester | Prucalopride Succinate |
| 4136-97-4 |
|
4-Amino-2-hydroxy-benzoic acid methyl ester | Prucalopride Succinate |
| 232941-14-9 |
|
4-Acetylamino-3-bromo-5-chloro-2-hydroxy-benzoic acid methyl ester | Prucalopride Succinate |
| 121-05-1 |
|
2-(Diisopropylamino) ethane-1,2-diamine | Acotiamide |
| 36635-61-7 |
|
p-toluenesulphonylmethyl isocyanide | Bempedoic acid |
| 54512-75-3 |
|
1-bromo-5-chloropentane | Bempedoic acid |
| 105-57-7 |
|
Acetaldehyde diethyl acetal / 1,1-Diethoxyethane | Imeglimin |
| CAS No | Structure | IUPAC Name | Application |
|---|---|---|---|
| 53184-78-4 |
|
tetrakis(4-hydroxyphenyl)methane | Polymers and electronics |
| 60532-63-0 |
|
tetrakis(4-aminophenyl)methane | Polymers and electronics |
| 630-76-2 |
|
Tetraphenylmethane | Polymers and electronics |
| 1844-01-5 |
|
4,4'-(Diphenylmethylene)diphenol | Polymers and electronics |
| 3010-81-9 |
|
Tris(4-methoxyphenyl) methanol | Polymers and electronics |
| 49757-42-8 |
|
4,4',4''-(Chloromethanetriyl)tris(methoxybenzene) | Polymers and electronics |
| 1121-89-7 |
|
Glutarimide | Anticancer drugs |
| 62595-74-8 |
|
3-Bromopiperidine-2,6-dione | Anticancer drugs |
| 30431-54-0 |
|
Bis[3,4,6-trichloro-2-(pentyloxycarbonyl)phenyl] Oxalate | Chemiluminescence applications |
| 2230613-03-1 |
|
2-(2-((R)-3-(3,4-Dimethoxyphenyl)-1-(((S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid, BDPIC Dundi PROTAC FKBP12-binding moiety 2 | Anticancer drugs |
| 2421153-77-5 |
|
ET-JQ1 OH; (R)-2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butanoic acid | Anticancer drugs |
| 2136247-12-4 |
|
MD-224 (acid); (3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide | Anticancer drugs |
| 172732-68-2 |
|
Varespladib; 2-(1-benzyl-2-ethyl-3-oxamoyl-1H-indol-4-yl)oxyacetic acid | Anti-inflammatory agent |
Pranetra LLP is established by visionary leaders in the field of chemical research and development, bringing a wealth of global experience to the forefront of our endeavours. Our focus is on delivering cutting-edge technology for Active Pharmaceutical Ingredients (APIs) intermediates, coupled with comprehensive Contract Development and Manufacturing Organization (CDMO) services.
Situated in Manesar, Gurgaon and having state-of-the-art facilities, Pranetra is home to a team of dedicated scientists who are at the forefront of inventing innovative product concepts. We stand resolutely on the pillars of innovation, quality, compliance, and reliability, ensuring that every aspect of our work reflects the highest standards in the industry.
More than just a service provider, we consider ourselves a trusted partner to our clients, collaborating closely to develop technology for key products. At Pranetra, we believe in forging partnerships that contribute to a healthier and sustainable future.
As we navigate the dynamic landscape of chemical research and development, Pranetra LLP remains dedicated to excellence, continuously striving to exceed expectations. We invite you to partner with us on this journey of innovation and growth as we work together towards a future that is not only prosperous for our business but also leaves a positive impact on the world around us.
Dr Ramnik has a proven track record of over two decades in API process development, optimization & scale-up, multi-step synthesis, scheme selection, costing, expertise in utilization of statistical tools like Minitab and Sigmatech for DOE in process optimization, particle size studies and solubility studies for addressing crystallization issues of APIs. He has developed around 50 APIs. Lately, he was Head of Chemical Research at Kimia Biosciences Ltd. and worked formerly with reputed organizations like Ranbaxy Labs Ltd and Sun Pharma, and is an expert in technology improvement and impurities synthesis as well.
Dr Soni has extensive global research experience in the area of drug discovery in major pharmaceutical organizations including Daiichi Sankyo Tokyo, Daiichi Sankyo India and Ranbaxy Research Laboratories. At Daiichi, Ajay designed and synthesized several compounds that went into early development. He also led the optimization and development of three clinical candidates. His expertise includes synthesis of complex and diverse chemical scaffolds such as carbohydrates, benzoxaboroles, macrolides, peptidomimetics etc. from milligram to kilogram scales to obtain finished product per ICH guidelines. He has a strong understanding of drug design parameters (both physicochemical as well as pharmacological and toxicological) and in in vivo PK-PD. He is well versed in toxicology analysis in the area of anti-infectives, anti-inflammation and cardiovascular diseases. He has authored several scientific publications and is the inventor on multiple patents.
Dr Khera has over 20 years of research experience in novel drug discovery and in synthetic organic chemistry. He has led and mentored research projects involving hit-to-lead optimizations for advancing molecules from early discovery to clinical development. He has served in senior positions in leading multinational pharmaceutical companies such as Daiichi Sankyo, Ranbaxy Research Laboratories and Dr Reddy’s Research Laboratories. His research interests include rational design of bioactive small molecules for therapeutic intervention, hit-to-lead optimization and development of new synthetic methodologies for lead compounds. He has a proven track record of working in collaborative research environments, while successfully driving challenging research projects in collaboration with GSK, Daiichi Sankyo etc. He has published several scientific articles and is the inventor on multiple patents.
Well-equipped laboratory having eight fume hoods presently with a team of well-trained scientists.
Our kilo-scale facility enables scale-up to kilogram scale, supporting seamless transition from lab to larger-scale manufacturing.
R&D and Office:
Third floor, Plot-20, Sector-3, Manesar, Gurgaon, Haryana-122050, INDIA.
Tel:
+91 9911 444 556 | +91 9818 337 315
Email:
pranetrallp@gmail.com
